Biogen Idec Inc (BIIB) 303.74 $BIIB
Why Express Scripts Inc., Monster Beverage Corporation, and Biogen Idec Inc. Are Today's 3 Worst Sto
John Divine, The Motley Fool - Motley Fool - Wed Jul 16, 6:45PM CDT
Seven of the stock market's 10 sectors finished higher today, as a second day of testimony from Federal Reserve Chairwoman Janet Yellen served to assure investors that interest rates will remain low indefinitely. With that in mind, stocks seem to be...
Arena Pharmaceuticals' Pain Candidate Gets New U.S. Patent - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Wed Jul 16, 3:30PM CDT
The U.S. Patent and Trademark Office issued a new patent to Arena Pharmaceuticals, Inc. (ARNA) for its pain candidate APD371.
Biogen Idec and Yahoo Health Spotlight Visionaries Whose Work Benefits People with Multiple Sclerosis (MS)
Business Wire - Wed Jul 16, 7:01AM CDT
Biogen Idec (NASDAQ:BIIB) announced today a new program with Yahoo Health to raise awareness of innovative efforts to help people with multiple sclerosis (MS) across the country. The MS Visionaries(TM) program showcases self-starters who have developed programs, tools or services to benefit the MS community. Profiles of these individuals are now featured on Yahoo Health, a new digital magazine covering modern health and wellness topics.
Hospira Upgraded to Strong Buy on Orchid Facility Buy - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Tue Jul 15, 4:00PM CDT
On Jul 12, Zacks Investment Research upgraded Hospira Inc. (HSP) to a Zacks #1 Rank (Strong Buy).
Biogen Idec Falls 2.42% on Heavy Volume: Watch For Potential Rebound
Comtex SmarTrend(R) - Tue Jul 15, 3:52PM CDT
Biogen Idec (NASDAQ:BIIB) traded in a range yesterday that spanned from a low of $311.92 to a high of $321.81. Yesterday, the shares fell 2.4%, which took the trading range below the 3-day low of $315.00 on volume of 1.4 million shares. Often times after large one-day declines, short-term traders may play for some degree of mean reversion.
After Yesterday's Decline of 2.42%, Biogen Idec Offers Investors Better Value
Comtex SmarTrend(R) - Tue Jul 15, 3:51PM CDT
Biogen Idec (NASDAQ:BIIB) traded in a range yesterday that spanned from a low of $311.92 to a high of $321.81. Yesterday, the shares fell 2.4%, which took the trading range below the 3-day low of $315.00 on volume of 1.4 million shares. Often times after large one-day declines, short-term traders may play for some degree of mean reversion.
CVS Caremark to Expand with Navarro Discount Pharmacy Buyout - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Tue Jul 15, 2:10PM CDT
Post-acquisition, CVS Caremark (CVS) will own Navarro's 33 retail drugstore locations and a specialty pharmacy named Navarro Health Services.
Will Abbott Laboratories (ABT) Miss This Earnings Season? - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Tue Jul 15, 11:40AM CDT
Abbott Labs (ABT) has a Zacks Rank #3 with an Earnings ESP of 0.00%.
Peregrine Pharmaceuticals' Q4 Loss Narrower than Expected - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Tue Jul 15, 10:00AM CDT
Peregrine Pharmaceuticals, Inc. (PPHM) reported a net loss of 6 cents per share in the fourth quarter of fiscal 2014.
Exelixis (EXEL) Soars: Stock Adds 23% in Session - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Tue Jul 15, 8:04AM CDT
Exelixis, Inc. (EXEL) was a big mover last session, as the company saw its shares rise 23% on the day.
IBD Big Cap 20 Leaders Hold Up Well Despite Shaky Market
at Investor's Business Daily - Mon Jul 14, 5:56PM CDT
A rising distribution day count in the major averages and an uptrend under pressure might lead some to believe that the market is in trouble -- poised for some sort of pullback. Not so fast. The charts of many IBD Big Cap 20 names don't reflect a...
Sunesis' Pediatric Plan Accepted in the EU - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Mon Jul 14, 5:45PM CDT
Sunesis Pharmaceuticals, Inc.'s (SNSS) Pediatric Investigation Plan for Qinprezo was accepted by the EMA???s Pediatric Committee for AML.
Will Johnson & Johnson (JNJ) Beat this Earnings Season? - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Mon Jul 14, 3:45PM CDT
Johnson & Johnson (JNJ) is scheduled to report second quarter 2014 results before the opening bell on Jul 15.
Bruker's Inspire Mapping System Fails to Inspire Share Prices - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Mon Jul 14, 2:20PM CDT
Bruker Corporation's (BRKR) Inspire is a self-optimizing pioneering scanning system that delivers 10-nanometer spatial resolution in chemical and materials property mapping.
Hefty Price Tag of Gilead's Sovaldi Questioned Again - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Mon Jul 14, 10:30AM CDT
Two members of the U.S. Senate Finance Committee issued a letter to Gilead asking it to justify the high price of Sovaldi.
Biogen's Profit Rolls Amid Recent Drug Launches
at Investor's Business Daily - Fri Jul 11, 6:14PM CDT
Profit at big-cap biotech stock Biogen Idec (BIIB) has risen every year since 1998, even climbing through recessions, thanks to strong drug offerings. The trend is expected to continue, with profit this year expected to rise 29% to $11.53 a share,...
Bristol-Myers to Seek U.S. Approval for Immuno-Oncology Drug - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Fri Jul 11, 4:30PM CDT
Bristol-Myers (BMY) will seek FDA approval for Opdivo in advanced melanoma by Sep 30.
Stocks Close Higher As Biotech, Internet Stocks Gain
at Investor's Business Daily - Fri Jul 11, 3:40PM CDT
Tech stocks outperformed Friday in an otherwise quiet, low-volume session. The Nasdaq, up most of the day, rose 0.4%. The Dow Jones industrial average climbed 0.2% and the S&P 500 edged up 0.1% after erasing modest losses. Volume fell 15% on the NYSE...
Oncolytics Up on Patient Enrolment Completion - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Fri Jul 11, 2:00PM CDT
Oncolytics Biotech Inc. (ONCY) finished enrolling patients in a phase II study (OSU-10045) on its oncology candidate, Reolysin.
Sarepta Therapeutics Slumps: SRPT Tanks 12.9% in Session - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Fri Jul 11, 7:42AM CDT
Sarepta Therapeutics has seen flat earnings estimate revisions for the current quarter along with a significant decline in its share price for the past month
Why Express Scripts Inc., Monster Beverage Corporation, and Biogen Idec Inc. Are Today's 3 Worst Sto
John Divine, The Motley Fool - Motley Fool - Wed Jul 16, 6:45PM CDT
Seven of the stock market's 10 sectors finished higher today, as a second day of testimony from Federal Reserve Chairwoman Janet Yellen served to assure investors that interest rates will remain low indefinitely. With that in mind, stocks seem to be...
Arena Pharmaceuticals' Pain Candidate Gets New U.S. Patent - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Wed Jul 16, 3:30PM CDT
The U.S. Patent and Trademark Office issued a new patent to Arena Pharmaceuticals, Inc. (ARNA) for its pain candidate APD371.
Biogen Idec and Yahoo Health Spotlight Visionaries Whose Work Benefits People with Multiple Sclerosis (MS)
Business Wire - Wed Jul 16, 7:01AM CDT
Biogen Idec (NASDAQ:BIIB) announced today a new program with Yahoo Health to raise awareness of innovative efforts to help people with multiple sclerosis (MS) across the country. The MS Visionaries(TM) program showcases self-starters who have developed programs, tools or services to benefit the MS community. Profiles of these individuals are now featured on Yahoo Health, a new digital magazine covering modern health and wellness topics.
Hospira Upgraded to Strong Buy on Orchid Facility Buy - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Tue Jul 15, 4:00PM CDT
On Jul 12, Zacks Investment Research upgraded Hospira Inc. (HSP) to a Zacks #1 Rank (Strong Buy).
Biogen Idec Falls 2.42% on Heavy Volume: Watch For Potential Rebound
Comtex SmarTrend(R) - Tue Jul 15, 3:52PM CDT
Biogen Idec (NASDAQ:BIIB) traded in a range yesterday that spanned from a low of $311.92 to a high of $321.81. Yesterday, the shares fell 2.4%, which took the trading range below the 3-day low of $315.00 on volume of 1.4 million shares. Often times after large one-day declines, short-term traders may play for some degree of mean reversion.
After Yesterday's Decline of 2.42%, Biogen Idec Offers Investors Better Value
Comtex SmarTrend(R) - Tue Jul 15, 3:51PM CDT
Biogen Idec (NASDAQ:BIIB) traded in a range yesterday that spanned from a low of $311.92 to a high of $321.81. Yesterday, the shares fell 2.4%, which took the trading range below the 3-day low of $315.00 on volume of 1.4 million shares. Often times after large one-day declines, short-term traders may play for some degree of mean reversion.
CVS Caremark to Expand with Navarro Discount Pharmacy Buyout - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Tue Jul 15, 2:10PM CDT
Post-acquisition, CVS Caremark (CVS) will own Navarro's 33 retail drugstore locations and a specialty pharmacy named Navarro Health Services.
Will Abbott Laboratories (ABT) Miss This Earnings Season? - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Tue Jul 15, 11:40AM CDT
Abbott Labs (ABT) has a Zacks Rank #3 with an Earnings ESP of 0.00%.
Peregrine Pharmaceuticals' Q4 Loss Narrower than Expected - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Tue Jul 15, 10:00AM CDT
Peregrine Pharmaceuticals, Inc. (PPHM) reported a net loss of 6 cents per share in the fourth quarter of fiscal 2014.
Exelixis (EXEL) Soars: Stock Adds 23% in Session - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Tue Jul 15, 8:04AM CDT
Exelixis, Inc. (EXEL) was a big mover last session, as the company saw its shares rise 23% on the day.
IBD Big Cap 20 Leaders Hold Up Well Despite Shaky Market
at Investor's Business Daily - Mon Jul 14, 5:56PM CDT
A rising distribution day count in the major averages and an uptrend under pressure might lead some to believe that the market is in trouble -- poised for some sort of pullback. Not so fast. The charts of many IBD Big Cap 20 names don't reflect a...
Sunesis' Pediatric Plan Accepted in the EU - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Mon Jul 14, 5:45PM CDT
Sunesis Pharmaceuticals, Inc.'s (SNSS) Pediatric Investigation Plan for Qinprezo was accepted by the EMA???s Pediatric Committee for AML.
Will Johnson & Johnson (JNJ) Beat this Earnings Season? - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Mon Jul 14, 3:45PM CDT
Johnson & Johnson (JNJ) is scheduled to report second quarter 2014 results before the opening bell on Jul 15.
Bruker's Inspire Mapping System Fails to Inspire Share Prices - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Mon Jul 14, 2:20PM CDT
Bruker Corporation's (BRKR) Inspire is a self-optimizing pioneering scanning system that delivers 10-nanometer spatial resolution in chemical and materials property mapping.
Hefty Price Tag of Gilead's Sovaldi Questioned Again - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Mon Jul 14, 10:30AM CDT
Two members of the U.S. Senate Finance Committee issued a letter to Gilead asking it to justify the high price of Sovaldi.
Biogen's Profit Rolls Amid Recent Drug Launches
at Investor's Business Daily - Fri Jul 11, 6:14PM CDT
Profit at big-cap biotech stock Biogen Idec (BIIB) has risen every year since 1998, even climbing through recessions, thanks to strong drug offerings. The trend is expected to continue, with profit this year expected to rise 29% to $11.53 a share,...
Bristol-Myers to Seek U.S. Approval for Immuno-Oncology Drug - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Fri Jul 11, 4:30PM CDT
Bristol-Myers (BMY) will seek FDA approval for Opdivo in advanced melanoma by Sep 30.
Stocks Close Higher As Biotech, Internet Stocks Gain
at Investor's Business Daily - Fri Jul 11, 3:40PM CDT
Tech stocks outperformed Friday in an otherwise quiet, low-volume session. The Nasdaq, up most of the day, rose 0.4%. The Dow Jones industrial average climbed 0.2% and the S&P 500 edged up 0.1% after erasing modest losses. Volume fell 15% on the NYSE...
Oncolytics Up on Patient Enrolment Completion - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Fri Jul 11, 2:00PM CDT
Oncolytics Biotech Inc. (ONCY) finished enrolling patients in a phase II study (OSU-10045) on its oncology candidate, Reolysin.
Sarepta Therapeutics Slumps: SRPT Tanks 12.9% in Session - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Fri Jul 11, 7:42AM CDT
Sarepta Therapeutics has seen flat earnings estimate revisions for the current quarter along with a significant decline in its share price for the past month
